This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
Context. MRTX0902 (Mirati Therapeutics) is an oral brain penetrating SOS1:KRAS protein-protein interaction inhibitor. Since the first report of the druggability…
molecule
1 year ago ●
5 mins read
Gleevec (imatinib) was the first tyrosine kinase inhibitor approved for the treatment of cancer and one of the first products…
Article
5 years ago ●
10 mins read
Context. “Compound 14” (Shionogi Pharmaceuticals) is a nicotinamide N-methyltransferase (NNMT) inhibitor. For some “difficult to drug” targets such as protein-protein…
molecule
1 year ago ●
4 mins read
Context. CC-99677 (BMS) is an oral, covalent MAPK–activated protein kinase-2 (MK2) inhibitor being developed for autoimmune diseases. Although p38 is…
molecule
1 year ago ●
4 mins read
Context. “Compound 23” (LEO Pharma) is an oral IL-17A protein−protein interaction modulator being developed for psoriasis and other inflammatory diseases.…
molecule
1 year ago ●
5 mins read
Context. BMS-986120 is an oral protease-activated receptor 4 (PAR4) inhibitor that was being developed for arterial thrombosis. PAR4 was long…
molecule
1 year ago ●
5 mins read
Load More
